FAQ: Tonix Pharmaceuticals TNX-2900 Phase 2 Trial for Prader-Willi Syndrome
Summary
Tonix Pharmaceuticals has received FDA clearance to begin a Phase 2 trial of TNX-2900 for Prader-Willi syndrome, a rare genetic disorder that causes life-threatening childhood obesity. The program has received Orphan Drug and Rare Pediatric Disease designations, making Tonix eligible for a transferable Priority Review Voucher upon approval.
What is TNX-2900 and what condition does it treat?
TNX-2900 is a proprietary magnesium-potentiated intranasal oxytocin formulation being developed for Prader-Willi syndrome (PWS), which is a rare genetic disorder and leading cause of life-threatening childhood obesity.
What recent milestone has Tonix achieved with TNX-2900?
The FDA has cleared Tonix’s Investigational New Drug application to begin a Phase 2 clinical trial for TNX-2900, allowing the company to advance the program to the next stage of clinical development.
What special designations has the TNX-2900 program received?
The program has received both Orphan Drug and Rare Pediatric Disease designations from the FDA, which makes Tonix eligible for a transferable Priority Review Voucher upon approval of the drug.
What other products does Tonix Pharmaceuticals have?
Tonix has FDA-approved Tonmya for fibromyalgia, markets two treatments for acute migraine in adults, and has development candidates for CNS disorders, immunology, immuno-oncology, and infectious diseases including TNX-801 for mpox and smallpox.
Where can I find more information about Tonix Pharmaceuticals?
Further information about Tonix can be found at www.tonixpharma.com and the latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP.
What is the significance of the Priority Review Voucher?
The transferable Priority Review Voucher that Tonix becomes eligible for upon approval can expedite the FDA review process for another drug application and can be sold to other pharmaceutical companies, providing additional value.
What stage of development is TNX-2900 currently in?
TNX-2900 is advancing into Phase 2 clinical trials, which represents the second stage of human testing following successful completion of Phase 1 safety studies.
What other CNS disorder treatments is Tonix developing?
Tonix is developing TNX-102 SL to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 239286